RheumatologyImmunologyPeer-reviewed journal article
Recapitulation of clinical features in a patient-derived xenograft mouse model of VEXAS Syndrome
Liliana AredeiD, Rita CoutinhoiD, Tiago L. DuarteiD, Marta LopesiD, Rui Vasco SimoesiD, Susana Pereira SilvaiD, Pedro BaptistaiD, José Manuel LopesiD, Raquel FariaiD, Delfim DuarteiD
Abstract
Patient-derived xenografts (PDX) are valuable tools to model human disease and test new therapies. Here, we report, for the first time, a PDX model recapitulating the unique characteristics of a VEXAS patient (unique patient number UPN1).
- Citations
- 4
- FWCI
- 0.98
- Field percentile
- top 28%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- BCM PDX Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management, as well as Visual Integration of Clinical and Omics Data
H. Dowst, A. McOwiti, … M. T. Lewis·bioRxiv·Feb 15, 2023
- Autologous humanized PDX modeling for immuno-oncology recapitulates the human tumor microenvironment
M. Chiorazzi, J. Martinek, … R. A. Flavell·bioRxiv·Aug 19, 2022
- Primary CD34+ cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistat
Daniel Nowak, Marie Demmerle, … Nanni Schmitt·bioRxiv·May 22, 2025
- Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis
Y. A. Evrard, A. SRIVASTAVA, … J. Morris·bioRxiv·Oct 2, 2019
- Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology
H. Bhatia^, A. T. Larsson^, … A. C. Hirbe·bioRxiv·Apr 29, 2022
- A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist
Binje Vick, Vindi Jurinović, … Irmela Jeremias·bioRxiv·Sep 26, 2025